

Supplemental Materials

Supplemental Table S1. Demographic and clinical characteristics of patients undergoing large bowel resection during primary debulking surgery

Variable	All patients (N=331)	
	n	%
Demographic and clinicopathologic characteristics		
Age at surgery, years ^a (range)	61 (26-91)	
BMI, kg/m ² ^a (range)	25.9 (16.3-50.9)	
Current smoker		
No	311	94
Yes	20	6
Former smoker		
No	207	63
Yes	124	37
Hypertension		
No	223	67
Yes	108	33
Diabetes		
No	313	95
Yes	18	5
Coronary artery disease		
No	325	98
Yes	6	2
AACCI group		
Low (score 0-1)	138	42
Intermediate (score 2-3)	159	48
High (score \geq 4)	34	10
Stage		
II	11	3
III	231	70
IIIA/B	5	1.5
IIIC	225	68
III NOS	1	0.3
IV	89	27
Histology		
High-grade serous	278	84
Low-grade serous	14	4
Endometrioid	5	1.5
Clear Cell	4	1
Mixed/Other	30	9
Preoperative CA-125, U/mL ^a (range)	486 (9-28503)	
Preoperative hemoglobin, g/dL ^a (range)	12.5 (8.4-14.9)	

Preoperative albumin, g/dL ^a (range)	4.1 (2.5-4.9)	
Operative characteristics		
Ascites, L ^a (range)	1.0 (0.0-13.0)	
Estimated blood loss, L ^a (range)	1.0 (0.1-6.0)	
Total intraoperative IV fluids, L ^a (range)	7.8 (1.3-23.7)	
Operative time, h ^a (range)	6.4 (2.1-14.9)	
Colon resection, non-rectosigmoid/descending		
No	213	64
Yes	118	36
Rectosigmoid/descending colon resection		
No	48	15
Yes	283	85
Total number of colon resections		
1	256	77
2	74	22
3	1	0.3
Cytoreductive status		
Optimal	302	91
Suboptimal	29	9
Residual disease		
0 cm	167	50.5
0.1-1 cm	135	40.8
> 1 cm	29	8.8
Postoperative characteristics		
Postoperative length of stay, days ^a (range)	9 (3-69)	
Major (Grade 3/4/5) postoperative complications		
0	251	76
1-2	76	23
3 or more	4	1
Anastomotic Leak		
No	310	94
Yes	21	6
Readmission within 30 days of surgery		
No	273	82
Yes	58	18
Readmission within 60 days of surgery		
No	225	77
Yes	76	23
Time from surgery to start of chemotherapy, days ^a (range)	40 (9-115)	
Number of upfront chemotherapy cycles		
0-4	12	4
5 or more	309	96

BMI, body mass index; AACCI, Age-Adjusted Charlson Comorbidity Index

^a Median


Supplemental Table S2. Factors associated with progression-free survival (PFS) and overall survival (OS)

Variable	PFS		OS	
	Adjusted HR (95% CI)	<i>p</i>	Adjusted HR (95% CI)	<i>p</i>
Age at surgery, years	1.01 (1.00 – 1.03)	.14	1.02 (0.99 – 1.05)	.12
BMI, kg/m ²	1.03 (1.00 – 1.05)	.03	1.03 (1.00 – 1.06)	.10
AACCI group				
Low (score 0-1)	Referent	--	Referent	--
Intermediate (score 2-3)	0.73 (0.49 – 1.08)	.12	0.73 (0.43 – 1.26)	.26
High (score ≥ 4)	0.73 (0.42 – 1.29)	.28	0.60 (0.27 – 1.35)	.22
Stage				
II	Referent	--	Referent	--
III	2.42 (0.76 – 7.77)	.14	0.94 (0.29 – 3.10)	.92
IV	3.21 (0.99 – 10.44)	.05	1.27 (0.38 – 4.30)	.70
Histology				
High-grade serous	Referent	--	Referent	--
Low-grade serous	0.84 (0.43 – 1.64)	.61	0.31 (0.08 – 1.29)	.11
Endometrioid	0.34 (0.04 – 3.32)	.35	NE	NE
Clear Cell	7.70 (2.34 – 25.32)	<.01	6.57 (1.54 – 28.12)	.01
Mixed/Other	1.41 (0.89 – 2.24)	.14	1.76 (1.01 – 3.07)	.05
Preoperative albumin, g/dL	0.80 (0.58 – 1.09)	.16	0.72 (0.48 – 1.08)	.11
Ileostomy				
No	Referent	--	Referent	--
Yes	0.97 (0.66 – 1.42)	.88	1.15 (0.69 – 1.93)	.60
Residual disease				
0 cm	Referent	--	Referent	--
0.1-1 cm	1.29 (0.99 – 1.68)	.06	1.27 (0.86 – 1.87)	.24
>1 cm	2.51 (1.59 – 3.97)	<.01	2.43 (1.43 – 4.13)	<.01
Number of chemotherapy cycles				
0-4	Referent	--	Referent	--
5 or more	0.48 (0.23 – 0.99)	.04	0.19 (0.08 – 0.42)	<.01

BMI, body mass index; NE, non-estimable

AACCI, Age-Adjusted Charlson Comorbidity Index

Supplemental Figure S1. Incidence and treatment of anastomotic leak in patients who did and did not undergo a diverting ileostomy



Supplemental Figure S2. Indications for 30-day readmission in patients with diverting ileostomy

